Morning Brief — September 10, 2026

Market Overview

Markets are navigating a treacherous macro backdrop as Brent crude has crossed $100/barrel for the first time since July, pushing Treasury yields higher and reigniting stagflation fears ahead of next week’s Fed meeting. ETF futures are down pre-bell Thursday on PPI data, suggesting yesterday’s selective rallies in pockets like retail earnings (ASO), mega-cap tech (META), and managed care (ELV) were stock-specific rather than broad risk-on. The macro tape — oil spike + rising yields — is a classic setup for defensive outperformance and growth underperformance, and that tension is visible in today’s divergent mover list.

Claude’s Call

DOWN — The PPI print landing into a $100 oil environment gives the Fed cover to stay hawkish, and with SPY already down pre-bell and bond yields ticking higher, the path of least resistance for the S&P 500 today is lower; yesterday’s winners (META, ELV, ASO) were earnings-driven outliers, not a market turn, and the broad tape looks heavy.

Top Movers

ASO (+14.4%) — $51.15 → $55.60 (+8.7% upside) Thesis: This is a genuine earnings beat driving a legitimate re-rating. Academy Sports posted $1.6B in Q2 revenue (+3% YoY), gross margin expanded 440 basis points, and management raised the full-year EPS outlook — all while the CEO openly acknowledged lower-income consumer pressure, which actually signals credibility rather than sandbagging. The e-commerce surge is a new wrinkle that wasn’t in the bull case. Technically, ASO is sitting almost exactly at the 50% Fibonacci retracement ($51.12) from the 6-month swing, which is the natural first resistance after a gap-up — not a red flag, but you want to see it hold above here before adding. Levels: Exit at the 23.6% fib retracement resistance at $55.60. Support at SMA-50 $46.94 — a close below there would break the thesis.

FTK (+14.4%) — $27.88 → $29.77 (+6.8% upside) Thesis: Flotek raised its 2026 revenue guidance to $360–370M on the back of stronger-than-expected international chemistry sales, and the data analytics segment surged 223% last quarter. That’s a real catalyst. However, the Wolfpack Research short report from August flagging a canceled deal that represented ~57% of near-term backlog hasn’t been fully resolved — that’s a serious overhang. Today’s bounce looks like a relief rally on the guidance raise, but the short thesis hasn’t been disproven. I’d be cautious chasing this one; it’s essentially a coin flip until Wolfpack’s claims are addressed by management with specifics. Levels: Exit at the 38.2% fib retracement resistance at $29.77. Support at SMA-50 $26.74 and the 50% fib at $26.97 — a close below $26.50 is trouble.

PLSE (+8.57%) — $52.97 → $64.52 (+21.8% upside) Thesis: A new analyst bull note is driving today’s pop in this medical device name, and the underlying catalyst is real — the NANOPULSE-AF pivotal trial for atrial fibrillation hit the halfway enrollment point ahead of schedule with 82 patients, which is a genuine positive clinical milestone. The stock has run 430%+ over three years and just completed a $75M equity offering, which is dilutive but also funds the runway to commercialization. Near the 6-month high at $54.71 — this is a momentum play with binary clinical risk baked in. If you’re not already in, chasing at near-6mo highs after a dilutive offering is speculative. Wait for a pullback to $46.20 (23.6% fib) before initiating. Levels: Exit at fib extension 1.272 at $64.52. Support at the 23.6% fib at $46.20 — a return to that level would be the proper entry, not today’s price.

CMPS (+8.05%) — $15.17 → $17.88 (+17.9% upside) Thesis: Legitimate biotech catalyst — 52-week Phase 3 data showing durable depression relief from COMP360 (psilocybin), with average depression score improvement of 13 points at the one-year mark. Management has a rolling FDA application underway with completion expected in Q4 2026 and a potential U.S. launch in H1 2027. The RSI at 16.02 is screaming deeply oversold — this stock has been beaten up, and today’s data gives the market a reason to reassess. At $15.17, sitting right at the 6-month high, there’s a clean breakout setup if FDA momentum continues. The psilocybin regulatory path is still novel and carries real binary risk, but the setup is compelling for risk-tolerant biotech traders. Levels: Exit at fib extension 1.272 at $17.88. Support at SMA-50 $13.12 — that’s your stop-loss line in the sand.

META (+6.55%) — $653.69 → $732.16 (+12.0% upside) Thesis: META is rallying on buzz around its new Muse AI agent, and at 28% revenue growth with a forward P/E of ~18.8x, this is a large-cap that screens modestly expensive vs. peers (peer median P/E is 11.4x) but the growth rate justifies a premium. Oppenheimer’s pushback — questioning whether consumers will pay for Muse when they already subscribe to Gemini and ChatGPT — is fair and worth watching. Technically, META hit its 20-day high today at $658 and sits well above its SMA-50 ($600.47). The WSB crowd is mixed (55% bullish), which means this isn’t a crowded euphoria trade. AI monetization is the question mark, but the core ads business is printing money. Levels: Exit at fib extension 1.272 at $732.16. Support at the 23.6% fib retracement at $649.52 — a tight stop just below today’s breakout.

ELV (+5.59%) — $419.07 → $466.30 (+11.3% upside) Thesis: Elevance Health is catching a sector bid alongside Molina (MOH +4.96%) — managed care is acting as a defensive rotation play in an oil-up, yields-up tape, which is exactly the playbook. ELV is also ex-dividend today ($1.72/share), so some of today’s move is technical (price adjusts down ex-div, stock is holding up anyway = real buying). The 6-month run is up nearly 48% and the stock is near its 6-month high of $426.79. RSI at 61.3 is elevated but not extreme. The Medicare Advantage plan discontinuation headwind in December is a known risk the market is aware of. Levels: Exit at fib extension 1.272 at $466.30. Support at the 23.6% fib at $392.51 and SMA-50 $397.23.

HPE (+5.12%) — $58.90 → $70.41 (+19.6% upside) Thesis: HPE reported a record Q3 with AI infrastructure demand driving results and expanded guidance — this is a real earnings catalyst. The stock is up 15.8% on the week and approaching its 6-month high of $59.82 (current is $58.90), so it’s within striking distance of a fresh breakout. HPE is a picks-and-shovels AI infrastructure play that doesn’t carry the valuation risk of pure-play AI names. If it clears $59.82 convincingly, the next target is the fib extension at $70.41. Be aware that without a volume surge (vol ratio is only 0.05), conviction behind this move is debatable. Levels: Exit at fib extension 1.272 at $70.41. Support at the 23.6% fib at $50.64 and SMA-50 $50.78.

CHYM (+6.93%) — $34.55 → $39.48 (+14.0% upside) Thesis: Chime is acquiring Stride Bank for $590M — the bank it has been renting to issue cards and hold deposits. This is a genuine strategic pivot: it eliminates rent-seeking from its banking partner, improves unit economics over time, and accelerates credit growth (per Morgan Stanley). The flip side is Chime just voluntarily walked into federal bank regulation, capital requirements, and FDIC oversight — none of which it has navigated before. Shares slashed early gains as the market digested that complexity. At forward P/E of ~20.3x vs peer median of ~14.6x, CHYM screens expensive. RSI at 22.51 suggests it was oversold before today, so this bounce has some technical juice, but the integration risk is real. Levels: Exit at fib extension 1.272 at $39.48. Support at the 23.6% fib at $30.28 — that’s your worst-case entry if the deal narrative deteriorates.

Headlines to Watch

  • Brent Crude Tops $100 — Yields Climb, Stocks Slide — Oil at triple digits with rising yields is the most dangerous macro combination for growth equities; watch whether the Fed interprets this as inflationary (hawkish) or demand-destructive (eventually dovish) — the answer shapes the next two weeks.

  • Apple Unveils First Foldable iPhone Under New CEO John Ternus — Shares barely moved (-0.3%), which tells you everything: the market sees this as a hardware upgrade cycle refresh, not a paradigm shift, and until AI monetization shows up in iPhone revenue, AAPL is in a show-me mode.

  • META’s Muse AI Agent — Game Changer or Subscription Fatigue? — Wall Street is divided on whether consumers will pay for another AI subscription; if Muse gets traction, META at ~19x forward earnings is still compelling, but Oppenheimer’s skepticism is the right frame for now.

  • HPE Q3: AI Infrastructure Demand Drives Record Results — This is the most investable AI infrastructure beat in today’s tape — HPE is cheap relative to pure-play AI names and benefits from the same capex cycle; the guidance raise here has legs.

  • Managed Care Sector Surge (ELV +5.6%, MOH +5.0%) — Classic defensive rotation into healthcare/managed care as oil spikes and yields rise — this is textbook sector rotation, and it has more room if the macro headwinds persist into next week’s Fed meeting.

  • NVDA Testing All-Time Highs, But WSB Turns Bearish (30% bullish) — When the retail crowd sours on NVIDIA at or near highs, it often precedes short-term consolidation; the stock is sitting right at the 23.6% fib support ($218.83 vs current $218.77) — that level needs to hold.

  • Micron (MU) Slides Despite JPMorgan Overweight — Rates and Oil Overpower the Call — When a major upgrade can’t hold a stock up, the tape is telling you something; MU is sitting below its 23.6% fib at $1,002.95 and WSB is 70% bearish — this is not the entry point.

Claude’s Top Picks

ASO (+14.4% today, +19.5% week) — $51.15 → $55.60 (+8.7% upside) Valuation: Deeply cheap — forward P/E of 7.3x vs peer median of 19.1x; even after today’s surge, this stock trades at less than half its peer group multiple. Upside: Raised full-year EPS guidance, 440bps gross margin expansion, and e-commerce surge are all durable positives that support a continued re-rating toward fair value. Risk: Lower-income consumer pressure is real and acknowledged by management — a macro deterioration (oil-driven inflation squeezing discretionary budgets) could pressure comps in Q3 and undercut the thesis.

CMPS (+8.05% today, +14.6% week) — $15.17 → $17.88 (+17.9% upside) Valuation: No earnings comps available (pre-revenue biotech), but at $15 with a potential FDA approval path in H1 2027, this is binary-risk pricing that still leaves room if the regulatory pathway clears. Upside: RSI of 16 coming off a deeply oversold base + 52-week Phase 3 durability data + rolling FDA application in motion = multiple catalysts stacking into year-end. Risk: Psilocybin regulatory approval is still novel and the FDA could apply unexpected scrutiny to the psychedelic drug class — a single negative advisory committee vote would hammer this stock 40-50% instantly.

HPE (+5.12% today, +15.8% week) — $58.90 → $70.41 (+19.6% upside) Valuation: No forward P/E comps provided, but HPE as a mature infrastructure name with a proven AI demand tailwind trading near its 6-month high is reasonably priced relative to hyperscaler peers. Upside: Record Q3 earnings + expanded guidance + AI server demand cycle is multi-year — HPE is a picks-and-shovels play that benefits from every hyperscaler capex dollar without carrying the valuation premium. Risk: Volume ratio of just 0.05 means today’s move lacks institutional conviction — a weak close near the 6-month high of $59.82 without a breakout would set up a short-term reversal.

ELV (+5.59% today, +3.3% week) — $419.07 → $466.30 (+11.3% upside) Valuation: No forward P/E comps in the dataset, but ELV at ~$419 after a 48% six-month run is pricing in a lot of the managed care re-rating already — valuation discipline required. Upside: Pure defensive rotation play — in an oil-up, yields-up, risk-off environment, managed care is the sector that wins, and ELV is the best-positioned large-cap name in the group with a dividend kicker (ex-div today). Risk: The Medicare Advantage plan wind-downs in December are a known headwind that will resurface in October when member notification letters go out — that’s a 6-8 week overhang.

AVO (+4.27% today, +4.7% week) — $13.42 → $16.76 (+24.9% upside) Valuation: No comps provided, but at $13.42 with revenue up 25.8% YoY, a 56% EPS beat, and $30M+ in Calavo synergies still being unlocked, this is an undervalued integration story. Upside: Calavo synergy target raised above $30M, avocado volumes surging 38%, and a strong Q4 setup with a full quarter of Calavo contribution — this is a compounding story in early innings. Risk: Avocado pricing has been a headwind (lower prices squeezed margins this quarter) — if pricing stays weak while costs rise, the volume growth won’t convert to bottom-line improvement.

Avoid

PLSE — Trading within 3% of its 6-month high at $54.71 after a 430% three-year run and a fresh dilutive $75M equity offering; the right entry is a pullback to the $46.20 fib support, not a chase at the highs.

FTK — The Wolfpack Research short report alleging a canceled deal representing ~57% of near-term backlog has NOT been resolved with specifics; today’s bounce on guidance is a relief rally into unresolved short-seller allegations — that’s a dangerous setup.

MGRT — RSI of 22.8, a stock at $118 that came from $6.46 six months ago (a 1,725% move), trading at 121x price-to-book (per the news), with Jim Cramer himself saying to take profits months ago and no recent company-specific news explaining today’s 5.4% move — this has all the hallmarks of a pump with no fundamental anchor.

WSB Sentiment Check

AAPL — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — The foldable iPhone is a real product cycle catalyst but shares barely moved on the launch day, sitting at $319.60 and below the SMA-50 at $316.93 — the technicals are neutral at best, and 80% WSB bullishness at near-highs is slightly frothy; this is a hold, not a chase.

MU — WSB says: BEARISH (30% bullish) Claude says: AGREE — MU just failed to hold its ground despite a JPMorgan Overweight upgrade, slipping in a $100-oil, rising-yield environment; sitting below the 23.6% fib at $1,002.95 with 70% WSB bears — the smart money is right here, and this isn’t the entry.

META — WSB says: MIXED (55% bullish) Claude says: AGREE — The 55% reading is actually the correct calibration; META at $653 is at its 20-day high and the Muse AI agent catalyst is real but unproven for monetization — this is a hold for existing longs, not a new entry at today’s gap-up price.

NVDA — WSB says: BEARISH (30% bullish) Claude says: PARTIALLY AGREE — NVDA at $218.77 is sitting literally on its 23.6% fib support at $218.83, which is a make-or-break level; a break below means a test of $208.54 (38.2% fib) and WSB bears would be right, but a hold here sets up a bounce — the technical setup is more interesting than the bearish consensus suggests, though I wouldn’t fight the macro tape by going long today.

AEO — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — AEO is trading at a 6-month low ($14.97 vs 6-month low of $14.75), sitting in a downtrend with all the fib support levels ABOVE current price — the technicals are bearish and 80% WSB bullishness on a stock in freefall is textbook retail catching a falling knife; this has no technical reason to reverse without a specific catalyst.

Earnings Scorecard

ASO — BEAT | Stock: +14.4% | Reported: Sep 9 (After Close) Reaction was fully justified — 440bps gross margin expansion, raised EPS guidance, and e-commerce acceleration are three distinct positives in one print; at 7.3x forward P/E vs 19.1x peer median, this stock was priced for disaster and got a pleasant surprise instead. Buy-the-dip on any pullback toward the $46.94 SMA-50.

INNV — REPORTED (EPS: -$0.08) | Stock: +4.85% | Reported: Sep 9 (After Close) Adjusted EBITDA surged 174-175% and the operational turnaround narrative is intact — the positive reaction on a GAAP loss is justified given the cash flow improvement story. Hold — the RSI at 3.3 was absurdly oversold and this is a technical normalization as much as a fundamental re-rating.

AVO — BEAT (EPS beat +56.5%) | Stock: +4.27% | Reported: Sep 9 (After Close) Reaction looks insufficient — a 56% EPS beat, $450M revenue up 25.8% YoY, and a raised synergy target above $30M deserved more than a 4% pop; the stock still sits 12% below analyst target of $16.50. Buy-the-dip — this is an underreaction, not a rip to sell.

M — REPORTED (EPS: $2.42) | Stock: -3.14% | Reported: Sep 10 (Before Open) Reaction somewhat justified — Macy’s raised full-year outlook but the market knows the beat came from sources (e.g., cost cuts, real estate) rather than core retail health; the -3% reaction while peers barely moved is the market being appropriately skeptical. Sell-the-rip on any bounces — the underlying retail thesis remains challenged.

CHWY — REPORTED (EPS: $0.65) | Stock: -2.41% | Reported: Sep 9 Reaction justified and arguably insufficient — headlines note a -10 to -11% intraday move on a free cash flow miss that overshadowed a raised outlook; FCF quality is the real metric for Chewy’s long-term value and the miss there is damning. Avoid until FCF inflects positively.

ADBE — REPORTED (EPS: $17.48) | Stock: -1.56% | Reported: Sep 9 With an analyst target of $277 and the stock likely trading well above that (given the data context), a -1.56% reaction to a strong earnings print suggests the market is selling the news after the stock ran into the print. Hold existing positions — the AI creative tools thesis is intact but near-term upside may be limited given positioning.

KR — REPORTED (EPS: $1.71) | Stock: +1.5% | Reported: Sep 9 Reaction looks right — Kroger is a defensive grocery name that should modestly outperform in an oil-up inflationary environment; a +1.5% reaction to a solid print is rational and the stock at $70.27 analyst target suggests fair value. Hold.

NAVN — REPORTED (EPS: -$3.87) | Stock: -22.83% | Reported: Sep 9 Despite 35% revenue growth, a -22.8% reaction on a business burning nearly $4/share signals the market is done being patient with loss-making growth stories in a rising yield environment — this is the macro punishing unprofitable growth. Avoid — this is a value trap until the path to profitability is clear.

This brief is for informational purposes only and does not constitute investment advice. All technical levels are based on the data provided. Past performance does not guarantee future results.